BTIG initiated coverage of Ideaya Biosciences with a Buy rating and $55 price target. Ideaya is a clinical-stage biotech company “with a robust pipeline of first-in-class molecules in attractive oncology markets and a strong balance sheet that offers multiple value-creation opportunities for investors,” the analyst tells investors in a research note. The firm says the company’s lead drug daroversitib has demonstrated encouraging clinical data in the untapped HLA-A2(-) uveal melanoma patient population.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $53 from $43 at RBC Capital
- Ideaya Biosciences price target raised to $50 from $40 at Oppenheimer
- Ideaya Biosciences reports Q4 EPS (52c), consensus (47c)
- IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- IDEAYA Biosciences Launches At-The-Market Offering Program
